Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults

Inclusion Criteria: * Moderate to severe asthma * Rescue inhaler 3 times per week * Be able to give informed consent * Must be on inhaled corticosteroid and long-acting beta agonist (LABA), (either individually or as a combination product) and report using a short-acting beta agonist (SABA) three or more times a week in at least 2 or 3 weeks prior to stud enrollment * Moderate or severe persistent asthma according to the National Heart, Lung, and Blood Institute (NHLBI) Guidelines, (EPR 2007) * At least one appointment scheduled with the asthma physician during the 4 weeks of participation. * Must be able to complete questionnaires over the phone or in person * Must be able to maintain a basic diary/log of inhaler use and any side effects for 30 days. Exclusion Criteria: * Severe psychiatric or cognitive problems * Known or suspected sensitivity to the investigational medication * Have a stenotic ear canal * Have a perforated ear drum * Active Otitis Media, Otitis Externa, or Mastoiditis * Allergic to Benzocaine * Unable to communicate in English * Any other significant cardiopulmonary disease * Smokers * Hospitalized in the last 6 months for pneumonia * Long term or lingering side effects to COVID19 * Lack of telephone or mobile phone * Subjects who have received any investigational drug for asthma in the past 60 days